CA-ANDERSEN-GLOBAL
11.11.2020 22:36:10 CET | Business Wire | Pressemeddelelse
Andersen fortsætter med at styrke sin problemfri service til kunder rundt om i verden, og deres brand følger efter, når Andersen Globals medlemsfirmaer i Mellemøsten nu opererer under brandet ”Andersen”. Meddelelsen kommer i forbindelse med optagelsen af brandet ”Andersen” blandt europæiske og latinamerikanske medlemsfirmaer tidligere i år.
Andersen Global-medlemsfirmaer, der tidligere opererede under brands ”Andersen Tax” og ”Andersen Tax & Legal” i Egypten, Jordan og Kuwait går nu over til det fælles brand ”Andersen”. Derudover byder Andersen velkommen til medlemsfirmaet Alrikaz i kongeriet Saudi-Arabien (KSA), som også tager Andersen-brandet til sig. Optagelsen af det fælles brand i regionen reflekterer på bedste vis det fulde omfang af den globale service, som Andersen-medlemsfirmaer tilbyder deres kunder, inklusive juridisk service i 16 lande, hvoraf to er i Mellemøsten.
Udover sine medlemsfirmaer i Egypten, Jordan, Kuwait og KSA er Andersen Global også tilstede i Mellemøsten i Bahrain, Libanon, Oman, Palæstina, Qatar og De Forenede Arabiske Emirater via samarbejdsfirmaer, med planer for fremtidig ekspansion.
”Vores optagelse af et fælles globalt brand viser hvor langt vi er kommet som organisation, og hvor vi er på vej hen”, sagde Mark Vorsatz, Andersen Global Chairman og Andersen CEO. ”Vi er engageret i at skabe en benchmarkingorganisation, som sætter den globale standard for den bedste uafhængige og synergistiske service i sin klasse. Vores fælles brand kendetegner vores problemfri service og delte centrale værdier rundt om i verden.”
Grundlaget for Andersens globale platform går helt tilbage til 2002, hvor 23 tidligere Arthur Andersen-partnere oprettede et firma, der kun beskæftigede sig med skat, WTAS LLC, som efterfulgtes af Andersen Global (tidligere WTAS Global) i 2014. Det samme år tog det grundlæggende amerikanske medlemsfirma brandet ”Andersen Tax” til sig, efterfulgt af medlemsfirmaer i Latinamerika, Europa og Afrika. Andersen Tax og Andersen Tax & Legal debuterede i Mellemøsten i 2017, og regionen er siden blevet udvidet til i dag at omfatte mere end 20 lokationer, 500 medarbejdere indenfor skat og jura, og næsten 100 partnere.
”Mellemøsten er et marked under udvikling, og skattebranchen er i fremgang, med særlig fokus på diversificering af økonomier,” sagde Fouad Al Hourani, Co-Regional Managing Director i Mellemøsten. ”Ved at tilbyde omfattende, problemfrie servicer, inklusive skat og jura, har vi lagt et solidt grundlag, og skabt en konkurrencedygtig platform for vores organisation i regionen.”
Lena Hamdi, Co-Regional Managing Director i Mellemøsten, tilføjer: ”Vores medlemsfirmaers servicetilbud gør os i stand til at opfylde vores kunders behov uanset grænser. Et fælles brand er en milepæl for vores organisation, og vi ser frem til dette næste trin af regionens udvikling.”
I løbet af det næste år fortsætter medlemsfirmaer i Afrika, Canada og Israel med at optage det fælles Andersen-brand, mens Andersen Global fortsætter med at udvide på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Siden oprettelsen i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 6.000 eksperter globalt og er repræsenteret på over 214 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20201111005886/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
